Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (261-270 of 320) with videos related to

Pageof 32
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2013
EGFR mutation analysis in sputum of lung cancer patients: a multitechnique studyA Jasmijn Hubers, Daniëlle A M Heideman, Yasushi Yatabe, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Lancet (London, England)|April 30, 2002
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trialHarm van Tinteren, Otto S Hoekstra, Egbert F Smit, et al.
International Journal of Cancer|February 13, 2004
Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ)Peter J F Snijders, Roderick H J Breuer, Thomas G Sutedja, et al.
Nature|October 25, 2019
Pan-cancer whole-genome analyses of metastatic solid tumoursPeter Priestley, Jonathan Baber, Martijn P Lolkema, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Pageof 32

Showing results (261-270 of 320) with videos related to

Sort By:
Pageof 32
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2013
EGFR mutation analysis in sputum of lung cancer patients: a multitechnique studyA Jasmijn Hubers, Daniëlle A M Heideman, Yasushi Yatabe, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Lancet (London, England)|April 30, 2002
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trialHarm van Tinteren, Otto S Hoekstra, Egbert F Smit, et al.
International Journal of Cancer|February 13, 2004
Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ)Peter J F Snijders, Roderick H J Breuer, Thomas G Sutedja, et al.
Nature|October 25, 2019
Pan-cancer whole-genome analyses of metastatic solid tumoursPeter Priestley, Jonathan Baber, Martijn P Lolkema, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Pageof 32